#USA #Executive Team #Gentuity #HF-OCT #Sudbury

Gentuity® Expands Executive Leadership Team

In a strategic move to bolster its growth and innovation, Gentuity, LLC has announced a significant expansion of its senior leadership team. The company, known for its pioneering work in intravascular High Frequency Optical Coherence Tomography (HF-OCT) imaging technology, has welcomed three seasoned professionals: Jason Rudy, Raj Kasbekar, and Alex Yildizyan. These appointments come at a critical juncture for Gentuity, aligning with its ambitions for accelerated expansion and innovation in the global market.

Strengthening Leadership for Next-Generation Innovation

Jason Rudy brings over 20 years of experience in interventional cardiology to Gentuity, having previously played a crucial role at St. Jude Medical where he helped launch the first coronary OCT platform. With leadership experience across major firms like Abbott, Biotronik, and Philips, Jason focuses on commercial strategy and has a proven history of advocating for new technologies in clinical settings. He expressed enthusiasm about Gentuity's future, highlighting the transformative potential of the HF-OCT platform in enhancing patient outcomes while managing costs. "I'm particularly passionate about increasing access to top-tier medical devices that drive efficiency in healthcare," he stated.

Meanwhile, Alex Yildizyan joins the company equipped with a decade of leadership in research and development, most recently as Vice President of R&D at Glaukos Corp. Renowned for his collaborative approach to innovation, Alex aims to help the R&D team at Gentuity navigate complex challenges and transform them into commercial successes. "My mission is to guide teams toward bringing innovative technology to fruition, which resonates deeply with Gentuity's objectives of advancing significant medical solutions," Yildizyan shared.

Additionally, Raj Kasbekar contributes his substantial expertise in biomedical engineering and regulatory affairs, having previously scaled Kaz USA from a $300M business to a $2B industry leader over his 16-year career. With four patents and a PhD focused on AI/ML applications, Kasbekar shows great promise in advancing Gentuity's products and expanding into new markets. His vision for the HF-OCT technology’s potential in new geographies aligns seamlessly with Gentuity's growth strategies. "The possibilities for HF-OCT technology spans various applications and territories; I'm eager to contribute to its decisively strategic growth," he commented.

Positioned for the Future

The ramifications of adding such formidable leaders to Gentuity's ranks are expected to manifest immediately, according to Desmond Adler, President of the company. He stated, "The expertise and innovative spirit that Jason, Alex, and Raj bring will not only amplify our capabilities but will also solidify our mission to enhance our HF-OCT platform's reach, ultimately providing groundbreaking technologies for clinicians and patients worldwide."

Gentuity is committed to building upon the success of its recently approved Prime Vis-Rx catheter, recognized as the world’s smallest and most deliverable intravascular imaging device. This device is uniquely indicated for pre-interventional use, marking a significant milestone in enhancing patient care within cardiovascular medicine.

About Gentuity

Located in Sudbury, MA, Gentuity operates at the forefront of medical technology, focused on developing next-generation intravascular imaging devices. The Gentuity High-Frequency OCT Imaging System stands out as the first commercial system capable of delivering Total Vessel Imaging using a micro-imaging catheter within a remarkable timeframe of less than one second. The company’s commitment to exploring new frontiers in cardiovascular care emphasizes its dedication to patient well-being – aiming for innovations that allow patients to live their lives to the fullest.

For media inquiries, please contact Candace Copher at [contact email].